<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02944162</url>
  </required_header>
  <id_info>
    <org_study_id>PG-0332</org_study_id>
    <nct_id>NCT02944162</nct_id>
  </id_info>
  <brief_title>CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML</brief_title>
  <official_title>Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First People's Hospital of Hefei</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hefei Binhu Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to study genetically engineered NK92 cell therapy in&#xD;
      treating patients with CD33 positive acute myeloid leukemias that is relapsed (after stem&#xD;
      cell transplantation or intensive chemotherapy) or refractory to further chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      Determine the safety and feasibility of the chimeric antigen receptor NK92 cells transduced&#xD;
      with the anti-CD33 vector (referred to as anti-CD33 CAR-NK cells).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. For patients with detectable disease, measure anti-leukemia response due to anti-CD33&#xD;
      CAR-NK cell infusions.&#xD;
&#xD;
      II. For patients with stored or accessible leukemia blasts, determine leukemia cell killing&#xD;
      by anti-CD33 CAR-NK in vitro.&#xD;
&#xD;
      III. Determine if cellular or humoral host immunity develops against the murine anti-CD33.&#xD;
&#xD;
      OUTLINE: Patients are assigned to 1 group according to order of enrollment.&#xD;
&#xD;
      Patients receive anti-CD33 CAR-NK (coupled with CD28, CD137 and CD3 zeta signalling domains)&#xD;
      vector-transduced NK92 cell line on days 0,3, and 5 in the absence of disease progression or&#xD;
      unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed intensively for 6 months, every 3&#xD;
      months for 2 years, and annually thereafter for 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events attributed to the administration of the anti-CD33 CAR-NK cells</measure>
    <time_frame>One year</time_frame>
    <description>Defined as &gt;= Grade 3 signs/symptoms, laboratory toxicities, and clinical events that are possibly, likely, or definitely related to study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to one year</time_frame>
    <description>Anti-leukemia responses to anti-CD33 CAR-NK cell infusions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Myeloid Leukemia With Maturation</condition>
  <condition>Acute Myeloid Leukemia Without Maturation</condition>
  <condition>ANLL</condition>
  <arm_group>
    <arm_group_label>CAR-NK Cell immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled patients will receive CAR-NK cells immunotherapy with a novel specific chimeric antigen receptor targeting CD33 antigen by infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD33 CAR-NK cells</intervention_name>
    <description>The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.</description>
    <arm_group_label>CAR-NK Cell immunotherapy</arm_group_label>
    <other_name>Chimeric antigen receptor NK92 cells with specificity for CD33</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects with CD33+ acute myeloid leukemia in patients with no&#xD;
             available curative treatment options (such as autologous or allogeneic SCT) who have&#xD;
             limited prognosis (&gt;12 weeks to &lt; 2 year survival) with currently available therapies&#xD;
             will be enrolled.&#xD;
&#xD;
          2. CD33+ acute myeloid leukemia CR (complete remission) can not be achieved after at&#xD;
             least 2 prior combination chemotherapy regimens.&#xD;
&#xD;
          3. AML in CR2 or CR3 and not eligible for allogeneic SCT because of age, comorbid&#xD;
             disease, or lack of available family member or unrelated donor.&#xD;
&#xD;
          4. Less than 1 year between last chemotherapy and progression (i.e. most recent&#xD;
             progression free interval &lt; 1 year).&#xD;
&#xD;
          5. Relapsed after prior autologous or allogenic SCT. AML patients with relapsed or&#xD;
             residual disease after at least 1 prior therapy and not eligible for allogeneic SCT.&#xD;
&#xD;
          6. Residual disease after primary therapy and not eligible for autologous SCT.&#xD;
&#xD;
          7. All of those patients must also meet the following criteria:&#xD;
&#xD;
        Expected survival &gt; 12 weeks. Creatinine &lt; 2.5 mg/dl ALT(alanine aminotransferase)/AST&#xD;
        (aspartate aminotransferase)&lt; 3x normal Bilirubin &lt; 2.0 mg/dl Any relapse after prior SCT&#xD;
        will make patient eligible regardless of other prior therapy.&#xD;
&#xD;
        Adequate venous access for apheresis, and no other contraindications for leukapheresis.&#xD;
&#xD;
        Ability to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or nursing women may not participate.&#xD;
&#xD;
          2. Active HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at the time&#xD;
             of screening.&#xD;
&#xD;
          3. Serious illness or medical condition which would not permit the patient to be managed&#xD;
             according to the protocol, including active uncontrolled infection, major&#xD;
             cardiovascular, coagulation disorders, respiratory or immune system, myocardial&#xD;
             infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or&#xD;
             psychiatric or emotional disorders.&#xD;
&#xD;
          4. History of severe immediate hypersensitivity to any of the agents including&#xD;
             cyclophosphamide, fludarabine, or aldesleukin.&#xD;
&#xD;
          5. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not&#xD;
             exclusionary.&#xD;
&#xD;
          6. The existence of unstable or active ulcers or gastrointestinal bleeding.&#xD;
&#xD;
          7. Patients need anticoagulant therapy (such as warfarin or heparin).&#xD;
&#xD;
          8. Patients need long-term antiplatelet therapy (aspirin at a dose &gt; 300mg/d; clopidogrel&#xD;
             at a dose &gt; 75mg/d).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lin Yang, Ph.D</last_name>
    <phone>86-512-65922190</phone>
    <email>info@persongen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PersonGen BioTherapeutics (Suzhou) Co., Ltd.</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215123</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Yang, Ph.D</last_name>
      <phone>86-512-65922190</phone>
      <email>info@persongen.com</email>
    </contact>
    <investigator>
      <last_name>Yangyi Bao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiang Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lin Yang, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>October 23, 2016</study_first_submitted>
  <study_first_submitted_qc>October 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2016</study_first_posted>
  <last_update_submitted>December 4, 2016</last_update_submitted>
  <last_update_submitted_qc>December 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>CD33</keyword>
  <keyword>CAR-NK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>(1) The use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access; (2) Seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and (3) Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

